Related Experiment Video
Updated: Aug 18, 2025
15:48
Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging
Published on: December 15, 2014
22.6K
Summary
Trastuzumab deruxtecan (T-DXd) shows superior efficacy compared to standard treatments for metastatic HER2-positive breast cancer. Emerging data suggests T-DXd may also benefit patients with HER2-low disease in neoadjuvant settings.
Area of Science:
- Oncology
- Medical research
- Clinical trials
Background:
- Metastatic HER2-positive breast cancer remains a significant clinical challenge.
- Existing treatments like capecitabine-based chemotherapy and trastuzumab deruxtecan-payload emtansine (T-DM1) have limitations.
- Trastuzumab deruxtecan (T-DXd) is an emerging targeted therapy for HER2-expressing cancers.
Purpose of the Study:
- To evaluate the efficacy of trastuzumab deruxtecan (T-DXd) compared to standard therapies in metastatic HER2-positive breast cancer.
- To explore the potential neoadjuvant role of T-DXd in HER2-low breast cancer.
Main Methods:
- Analysis of phase III clinical trial data from DESTINY-Breast02 and DESTINY-Breast03.
- Review of results from the investigator-initiated TRIO-US B-12 TALENT trial.
Main Results:
- T-DXd demonstrated superior outcomes compared to capecitabine-based chemotherapy in DESTINY-Breast02.
- T-DXd showed improved efficacy over T-DM1 in DESTINY-Breast03.
- The TRIO-US B-12 TALENT trial suggests potential neoadjuvant activity of T-DXd in HER2-low breast cancer.
Conclusions:
- Trastuzumab deruxtecan (T-DXd) represents a significant advancement in treating metastatic HER2-positive breast cancer.
- T-DXd offers a more effective treatment option than current standards of care.
- Further investigation into T-DXd for HER2-low disease, particularly in the neoadjuvant setting, is warranted.
